US Patent 10918680 Phage therapy of
Patent 10918680 was granted and assigned to Pherecydes Pharma on February, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+314 characters)
Article
Patent abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Edits on 9 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Flavie Pouillot0
Hélène Blois0
Edits on 5 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
109186800
Date of Patent
February 16, 2021
0Patent Application Number
151107690
Date Filed
January 9, 2015
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10918680 Phage therapy of
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10918680
Date of patent
February 16, 2021
Patent application number
15110769
Date Filed
January 9, 2015
Patent citations
Patent primary examiner
Find more entities like US Patent 10918680 Phage therapy of
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.